OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges
Alice Indini, Daniela Massi, Matteo Pirro, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 477-490
Open Access | Times Cited: 20
Alice Indini, Daniela Massi, Matteo Pirro, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 477-490
Open Access | Times Cited: 20
Showing 20 citing articles:
Application of artificial intelligence for improving early detection and prediction of therapeutic outcomes for gastric cancer in the era of precision oncology
Zhe Wang, Yang Liu, Xing Niu
Seminars in Cancer Biology (2023) Vol. 93, pp. 83-96
Closed Access | Times Cited: 45
Zhe Wang, Yang Liu, Xing Niu
Seminars in Cancer Biology (2023) Vol. 93, pp. 83-96
Closed Access | Times Cited: 45
Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies
D.Y. Luo, Jing Zhou, Shuiliang Ruan, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
D.Y. Luo, Jing Zhou, Shuiliang Ruan, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy
Haisheng Yu, Jing Liu, Xia Bu, et al.
Cell chemical biology (2023) Vol. 31, Iss. 4, pp. 776-791.e7
Open Access | Times Cited: 34
Haisheng Yu, Jing Liu, Xia Bu, et al.
Cell chemical biology (2023) Vol. 31, Iss. 4, pp. 776-791.e7
Open Access | Times Cited: 34
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies
Siwei Zheng, Wenwen Wang, Lesang Shen, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 14
Siwei Zheng, Wenwen Wang, Lesang Shen, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 14
Cancer immune exclusion: breaking the barricade for a successful immunotherapy
Sofía Bruni, María F. Mercogliano, Florencia Mauro, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Sofía Bruni, María F. Mercogliano, Florencia Mauro, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
HIF-1α Mediates Immunosuppression and Chemoresistance in Colorectal Cancer by Inhibiting CXCL9, −10 and −11
Yixi Su, Jiaqi Liu, Yu Tian, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116427-116427
Open Access | Times Cited: 4
Yixi Su, Jiaqi Liu, Yu Tian, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116427-116427
Open Access | Times Cited: 4
Cutaneous melanoma
Alpaslan Tasdogan, Ryan J. Sullivan, Alexander Katalinic, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access
Alpaslan Tasdogan, Ryan J. Sullivan, Alexander Katalinic, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access
NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets
Alice Indini, Irene Fiorilla, Luca Ponzone, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9985-9985
Open Access | Times Cited: 18
Alice Indini, Irene Fiorilla, Luca Ponzone, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9985-9985
Open Access | Times Cited: 18
NIR-activated Janus nanomotors with promoted tumor permeability for synergistic photo-immunotherapy
Yingying Zhang, Yujuan Xing, Hong Zhou, et al.
Acta Biomaterialia (2024)
Closed Access | Times Cited: 3
Yingying Zhang, Yujuan Xing, Hong Zhou, et al.
Acta Biomaterialia (2024)
Closed Access | Times Cited: 3
Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer
Yuanfeng Wei, Lingnan Zheng, Xi Yang, et al.
The Oncologist (2023) Vol. 28, Iss. 11, pp. e1052-e1064
Open Access | Times Cited: 9
Yuanfeng Wei, Lingnan Zheng, Xi Yang, et al.
The Oncologist (2023) Vol. 28, Iss. 11, pp. e1052-e1064
Open Access | Times Cited: 9
Peptide degrader‐based targeting of METTL3/14 improves immunotherapy response in cutaneous melanoma
Hong Han, Zenghui Li, Yuqing Feng, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 48
Closed Access | Times Cited: 2
Hong Han, Zenghui Li, Yuqing Feng, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 48
Closed Access | Times Cited: 2
Tumor infiltrating lymphocytes (TILs) – pathologia, quo vadis? - A global survey
Kristijan Skok, Konstantin Bräutigam
Pathology - Research and Practice (2024) Vol. 266, pp. 155775-155775
Open Access | Times Cited: 1
Kristijan Skok, Konstantin Bräutigam
Pathology - Research and Practice (2024) Vol. 266, pp. 155775-155775
Open Access | Times Cited: 1
Systematic pan-cancer analysis of the nicotinamide n-methyltransferase in human cancer
Li Cao, Wei Wu, Xiangyu Deng, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 4
Li Cao, Wei Wu, Xiangyu Deng, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 4
Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer
Renyu Liu, Ting Yang, Jinyu Huang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
Renyu Liu, Ting Yang, Jinyu Huang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
Enhancing cancer immunotherapy and antiangiogenic therapy by regulating gut microbes: Opportunities and challenges
Jie Xu, Yaomei Tian, Die Hu, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 3
Open Access
Jie Xu, Yaomei Tian, Die Hu, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 3
Open Access
Immunogenic cell death: A new strategy to enhancing cancer immunotherapy
Lei Dou, Yu Fang, Huiyuan Yang, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access
Lei Dou, Yu Fang, Huiyuan Yang, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access
Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective
Stefano Poletto, Luca Paruzzo, Alessandro Nepote, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 101-101
Open Access | Times Cited: 1
Stefano Poletto, Luca Paruzzo, Alessandro Nepote, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 101-101
Open Access | Times Cited: 1
Peptide degrader‐based targeting of METTL3/14 improves immunotherapy response in cutaneous melanoma
Hong Han, Zenghui Li, Yuqing Feng, et al.
Angewandte Chemie (2024) Vol. 136, Iss. 48
Open Access
Hong Han, Zenghui Li, Yuqing Feng, et al.
Angewandte Chemie (2024) Vol. 136, Iss. 48
Open Access
Nanomedicines: Targeting inflammatory pathway in cancer and aging
Olga Sukocheva, Yonggang Zhang
Seminars in Cancer Biology (2022) Vol. 86, pp. 1218-1221
Closed Access | Times Cited: 1
Olga Sukocheva, Yonggang Zhang
Seminars in Cancer Biology (2022) Vol. 86, pp. 1218-1221
Closed Access | Times Cited: 1
Tumormikromilieu des Melanoms – Einfluss moderner Therapien
Judith Sirokay, Cornelia Mauch
Deleted Journal (2022) Vol. 73, Iss. 12, pp. 907-914
Closed Access | Times Cited: 1
Judith Sirokay, Cornelia Mauch
Deleted Journal (2022) Vol. 73, Iss. 12, pp. 907-914
Closed Access | Times Cited: 1
